Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 73Lymphoma 66Hodgkin Disease 52Lymphoma, Non-Hodgkin 48Recurrence 24Lymphoma, Extranodal NK-T-Cell 19Lymphoma, T-Cell, Peripheral 18Lymphoma, Follicular 18Lymphoma, Mantle-Cell 14Neoplasms 13Lymphoma, T-Cell 13Precursor Cell Lymphoblastic Leukemia-Lymphoma 12Lymphoma, Large-Cell, Anaplastic 11Lymphoma, B-Cell 11Lymphoma, T-Cell, Cutaneous 10Leukemia, Lymphocytic, Chronic, B-Cell 10Burkitt Lymphoma 10Mycosis Fungoides 9Lymphoma, Large-Cell, Immunoblastic 9Lymphoma, B-Cell, Marginal Zone 9Immunoblastic Lymphadenopathy 9Sezary Syndrome 8Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 6Pancreatic Neoplasms 6Neoplasm Metastasis 5Leukemia 5Breast Neoplasms 5Waldenstrom Macroglobulinemia 4Sarcoma 4Lung Neoplasms 4

Interventions

siltuximab 2fludarabine phosphate 2fludarabine 2Interleukin 1 Receptor Antagonist Protein 2Cyclophosphamide 2AP 1903 reagent 2obinutuzumab 1glofitamab 1axicabtagene ciloleucel 1Oxaliplatin 1Neuropsychological Tests 1Magnetic Resonance Spectroscopy 1Gemcitabine 1Gelsolin 1Contrast Media 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cytokine Release Syndrome × Gemcitabine × Lymphoid × Clear all
NCT06806033 2026-05-26

A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

Hoffmann-La Roche

Phase 2 Recruiting
100 enrolled
Lymphoid

Cytokine Release Syndrome, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡